R ARIVANANTHAM
CHENNAI, MAR 26
In a landmark medical achievement, MGM Healthcare has established the world’s largest intestinal rehabilitation and transplant program in just three years—setting a new global benchmark in one of medicine’s most complex domains.
- MGM Healthcare builds world’s largest intestinal rehab & transplant ecosystem from scratch
- 40+ transplants, including a record 21 in 2025, mark the highest annual global volume
- Home-based TPN, Dorbimex-led infection control, and ‘Back to Base’ transport power success
- 98% patients freed from TPN; survival outcomes rival top US & European centres
- India’s first Transplant Oncology program opens new frontier in complex cancer care
Since its inception of this programme, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone, the highest annual volume recorded anywhere in the world.
The program was conceived under the leadership of Prof. Dr. Anil Vaidya, Chair and Director, Institute of Multi-Visceral and Abdominal Organ Transplant, following his return from the Cleveland Clinic. A multidisciplinary team comprising Dr. Senthil Muthuraman, Dr. Venkatesh BS, Dr. Sivakumar Mahalingam, and Dr. Manoj Prabhakar, along with intensivists and anaesthetists, including Dr. C. P. Dinesh Babu, Late Dr. Nivash Chandrashekar, and Dr. Saravanan, has scaled the initiative into a comprehensive, world-class service.
A global reference point in complex care
Commenting on the success, Prof. Dr. Anil Vaidya said: “Intestinal rehabilitation and transplantation is among the most complex and resource-intensive domains in medicine. It replaces the failing intestine with a donor organ, restoring the body’s ability to absorb nutrients naturally. By building the world’s largest program in this domain, we have positioned Chennai as a global reference point. This was not just about creating a transplant program, but an integrated ecosystem spanning surgery, rehabilitation, home-based care, infection control, and long-term monitoring.”
The program has delivered world-class one- and three-year survival rates, often matching or surpassing leading centres in the US and Europe. Crucially, 98% of patients are free from total parenteral nutrition (TPN)—a major milestone in long-term recovery.
Given the risks of prolonged TPN, including infections, liver damage, and compromised quality of life, this outcome signals true physiological recovery and return to normal living.
Pushing the frontiers of transplant medicine
Beyond scale and outcomes, the initiative has redefined possibilities in advanced care. It has led to the creation of India’s first Transplant Oncology program—only the third globally—offering intestinal transplantation as a curative option for patients with inoperable pseudomyxoma peritonei.
This marks a paradigm shift, extending transplantation into complex malignancies once considered terminal, opening an entirely new therapeutic frontier.
Three pillars of breakthrough success
Prof. Dr. Vaidya added: “At the core of this program’s success are three defining innovations. The first is the establishment of a robust, home-based total parenteral nutrition (HPN) program, which supports patients outside the hospital setting. The second is the introduction of a novel, patented antiseptic solution, known as Dorbimex, used as a spray for central line care. When combined with meticulous protocols in catheter maintenance, stoma care, and wound management, this innovation has driven central line infection rates to near zero. A third, and defining differentiator of this program, has been the development of a specialised critical care transport network – the ‘Back to Base’ model. Patients with acute intestinal loss are now safely transferred to Chennai from across India, including Mumbai, Delhi, Agra, Kolkata, and Goa, thanks to across air, road, and even train-based critical care transport, a first-of-its-kind initiative in India.”
Redefining India’s role in advanced medicine
Prof. Dr. Vaidya emphasised: “What has emerged is more than a clinical program – it reflects how high-complexity care can be thoughtfully designed and scaled in India. It also underscores that innovation in care delivery, not just technology, is critical to improving outcomes, and that leadership in advanced medicine is no longer limited by geography.”
